
Mirum Pharmaceuticals rose 26.8% from $72.21 to $91.58, ahead of the S&P 500's +11.2%. Its worst day was Feb 26 (−15.1%), and its low came Dec 15 at $64.10.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Mirum Pharmaceuticals closed at its lowest level of the year, 11.2% below where the year started.
−1.4% · S&P 500 −0.2%
EPS of $-0.12 missed the $0.04 estimate on $148.9M revenue (est. $141.6M); FY revenue guidance of $630.0M–$650.0M against the $645.9M consensus.
Story events cover the past 12 months · Times ET
−15.1%, the year's worst day · S&P 500 −0.6%
EPS of $-0.50 missed the $-0.36 estimate on $159.9M revenue (est. $148.2M); FY revenue guidance of $660.0M–$680.0M against the $644.3M consensus.
−6.5% · S&P 500 −0.3%
Mirum Pharmaceuticals shares fell 8.3%, while the S&P 500 fell 1.2%.
−8.3% · S&P 500 −1.2%
Mirum Pharmaceuticals closed at its highest level of the year, 78.1% above where the year started.
+0.2% · S&P 500 −0.3%
EPS of $-0.80 beat the $-0.80 estimate on $176.2M revenue (est. $165.5M); FY revenue guidance of $680.0M–$700.0M against the $675.1M consensus.
−11.0% · S&P 500 −0.2%
EPS of $-0.87 missed the $-0.44 estimate on $185.7M revenue (est. $177.7M); FY revenue guidance of $715.0M–$720.0M against the $697.2M consensus.
+11.4%, the year's best day · S&P 500 +1.7%
Where it ended: a close of $91.58 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.58, revenue est. $194.2M).
Nothing in the past 12 months.
All MIRM dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MIRM and SPY from Benzinga historical bars. Not investment advice.